Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 1/20 | 0.32 |
| ▸ | SDC2 | P34741 | 1/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137891 | 0.92 | CTSK (0.35) | PYGBCTSSCTSKKLK5 | |
| SCHEMBL21058397 | 0.92 | CTSK (0.35) | PYGBCTSSCTSKKLK5 | |
| SCHEMBL21138667 | 0.83 | PYGB (0.36) | PYGB | |
| Hydrochloric Acid SCHEMBL29777456 | 0.82 | PYGB (0.36) | PYGB | |
| SCHEMBL25957442 | 0.81 | CTSK (0.36) | PYGBCTSSCTSK | |
| SCHEMBL31353010 | 0.81 | CAPN1 (0.40) | PYGBCTSSCTSK | |
| SCHEMBL21137968 | 0.79 | PYGB (0.38) | PYGB | |
| SCHEMBL21058338 | 0.79 | MEN1 (0.36) | PYGB | |
| SCHEMBL21138004 | 0.79 | MEN1 (0.36) | PYGB | |
| SCHEMBL23104926 | 0.77 | PYGB (0.39) | PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115215911-B | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-115215911-A | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-109929001-B | Glucosamine derivative, composition thereof and medical application thereof | 润佳（苏州）医药科技有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | SDCBP 2770/4885SDC2 3894/4885PYGB 760/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | SDCBP 2770/4885SDC2 3894/4885PYGB 760/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | SDCBP 3911/4885SDC2 4329/4885PYGB 601/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | SDCBP 3911/4885SDC2 4329/4885PYGB 601/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | SDCBP 3911/4885SDC2 4329/4885PYGB 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.